Rudy Dekeyser is managing partner of LSP’s Health Economics Funds (LSP HEF) with 400M€ under management and investing in later stage medical device, diagnostic and digital health companies in Europe and the US. Prior to joining LSP in 2012, Rudy has been managing director of VIB, an entrepreneurial life sciences research institute which he co-founded.

Rudy has been/is chairman/non-executive director at many company boards including Ablynx (acquired by Sanofi), Actogenix (acquired by Intrexon), Multiplicom (acquired by Agilent), CropDesign (acquired by BASF), Devgen (acquired by Syngenta), QBiologicals (acquired by Amatsi), Curetis (listed), Sequana Medical (listed), Celyad (listed).

Rudy is chairman/board member at several non-profit life sciences initiatives such as EMBLEM, De Weijerhorst Stichting, Hubrecht Organoid Technology, Fonds Généret, the Medical Advisory Board of the Koning Boudewijn Stichting and the Fonds Fournier-Majoie.